Moderna shares continue to fall even as its 3 vaccines enter final stage trials

March 28, 2024 01:19 AM AEDT | By Invezz

Moderna shares continue to fall even as its 3 vaccines enter final stage trials — Image source: Invezz

Moderna’s 3 vaccines advance

Despite the stock decline, Moderna announced positive clinical trial results for three experimental vaccines targeting various viruses.

These vaccines have progressed to the final stage of studies, indicating a step forward for the company in diversifying its product portfolio beyond COVID-19 shots, which currently constitute its sole commercially available product.

How did the markets react?

Shares of Moderna had initially surged by over 3% in premarket trading on Wednesday following the announcement of the positive trial data.

The company is set to provide further insights into its post-Covid-19 strategy during its fifth annual “Vaccines Day” investor event in Boston.

Moderna aims to capitalize on the estimated $52 billion market for infectious disease shots, including vaccines targeting respiratory diseases and latent viruses.

Targeting latent viruses

Moderna’s CEO Stéphane Bancel highlighted the significance of addressing latent viruses, which can remain dormant in the body and lead to serious health complications later in life.

The absence of approved vaccines for several latent viruses presents an opportunity for Moderna to fill this unmet medical need. The company plans to present new clinical trial data on vaccines targeting latent viruses, including shots against norovirus, Epstein-Barr virus, and the virus responsible for shingles and chickenpox.

Moderna is expanding vaccine portfolio

In addition to COVID-19 vaccines, Moderna is advancing several other vaccine candidates through late-stage clinical trials. These include a combination vaccine for COVID-19 and the flu, a vaccine against cytomegalovirus (CMV), and a jab targeting respiratory syncytial virus (RSV).

The company also revealed plans to introduce a “next-generation” COVID-19 shot, which demonstrated a stronger immune response than its current vaccine in late-stage trials.

The post Moderna shares continue to fall even as its 3 vaccines enter final stage trials appeared first on Invezz

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.